Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.